MiMedx Group has been granted a patent for compositions containing amniotic fluid, a carrier, and placental tissue components. The patent also covers systems for administering these compositions. GlobalData’s report on MiMedx Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights MiMedx Group Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MiMedx Group, Cardiothoracic surgery instruments was a key innovation area identified from patents. MiMedx Group's grant share as of February 2024 was 60%. Grant share is based on the ratio of number of grants to total number of patents.

Amniotic fluid compositions kit with administration device

Source: United States Patent and Trademark Office (USPTO). Credit: MiMedx Group Inc

A recently granted patent (Publication Number: US11865142B2) discloses a kit designed for medical applications, comprising a first composition of modified amniotic fluid that has been sterilized and desalted, a second composition with a pharmaceutically acceptable carrier, and an administration device with dual chambers and apertures for expelling the compositions. The modified amniotic fluid in the kit is specified to be free of salts, cells, and cellular debris, with a controlled salt concentration and particle size, making it suitable for various medical treatments.

The kit's applications include treating gastrointestinal, skin, and pulmonary diseases, preventing scar formation, enhancing wound healing, and reducing scar tissue post-surgery in different areas of the body. The method involves administering the modified amniotic fluid composition to patients using the kit, with specific weight ratios and viscosity ranges for optimal effectiveness. The pharmaceutically acceptable carrier options include aqueous carriers, biocompatible gelation agents, polysaccharides, and collagen, with a focus on human collagen like Wharton's jelly or placental collagen. This patented kit offers a comprehensive solution for medical professionals in various fields to address a range of conditions and procedures effectively.

To know more about GlobalData’s detailed insights on MiMedx Group, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies